Efficacy and safety of immune checkpoint inhibitor plus bevacizumab-based chemotherapy in advanced or recurrent KRAS-mutant non-squamous NSCLC: the SPIRAL-STONE study.
Ishida M, Yamada T, Kamada R, Hibino M, Egami M, Nakano T, Imabayashi T, Takumi C, Ishida K, Takeshita M, Masubuchi K, Izumi M, Ota T, Morito S, Chihara Y, Hirai S, Shiotsu S, Sawada R, Kawachi H, Nishioka N, Iwasaku M, Takayama K